Intermittent MEK inhibition for the treatment of metastatic uveal melanoma

Khan, S., Patel, S. P., Shoushtari, A. N., Ambrosini, G., Cremers, S., Lee, S., Franks, L., Singh-Kandah, S., Hernandez, S., Sender, N., Vuolo, K., Nesson, A., Mundi, P., Izar, B., Schwartz, G. K., & Carvajal, R. D. (2022). Intermittent MEK inhibition for the treatment of metastatic uveal melanoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.975643
Authors:
Shaheer Khan
Sapna P. Patel
Alexander N. Shoushtari
Grazia Ambrosini
Serge Cremers
Shing Yip Lee
Lauren Franks
Shahnaz Singh-Kandah
Susana Hernandez
Naomi Sender
Kristina Vuolo
Alexandra Nesson
Prabhjot S. Mundi
Benjamin Izar
Gary K. Schwartz
Richard D. Carvajal
Affiliated Authors:
Shaheer Khan
Grazia Ambrosini
Serge Cremers
Shing Yip Lee
Lauren Franks
Shahnaz Singh-Kandah
Susana Hernandez
Naomi Sender
Kristina Vuolo
Alexandra Nesson
Prabhjot S. Mundi
Benjamin Izar
Gary K. Schwartz
Richard D. Carvajal
Columbia Affiliation:
Subjects:
Ocular Cancer Research and Treatment (OpenAlex Topic)
Diagnosis and Treatment of Multiple Myeloma (OpenAlex Topic)
Ubiquitin-Proteasome Proteolytic Pathway (OpenAlex Topic)
Author Keywords:
uveal melanoma
metastatic
mek inhibition
intermittent dosing
selumetinib
elink
Publication Type:
Article
Unique ID:
10.3389/fonc.2022.975643
PMID:
36249046
DOI:
10.3389/fonc.2022.975643
Journal:
Frontiers in Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: